- Home
- IRWD
as 12-17-2024 4:00pm EST
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 510.5M | IPO Year: | 2010 |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.06 - $15.70 | Next Earning Date: | 02-13-2025 |
| Revenue: | $378,418,000 | Revenue Growth: | -12.48% |
| Revenue Growth (this year): | -18.59% | Revenue Growth (next year): | -1.40% |
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Emany Sravan Kumar | IRWD | SVP, COO and CFO | Nov 18 '24 | Sell | $4.08 | 11,001 | $44,884.08 | 309,572 | |
| Davis Andrew | IRWD | SVP, Chief Business Officer | Nov 18 '24 | Sell | $4.08 | 5,360 | $21,868.80 | 284,685 |
Latest Ironwood Pharmaceuticals Inc. News
IRWD Breaking Stock News: Dive into IRWD Ticker-Specific Updates for Smart Investing
Argus Research
7 days ago
IRWD: What does Argus have to say about IRWD?
Simply Wall St.
8 days ago
High Growth Tech Stocks In The United States To Watch
Argus Research
14 days ago
IRWD: What does Argus have to say about IRWD?
Business Wire
22 days ago
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
Business Wire
a month ago
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Argus Research
a month ago
IRWD: What does Argus have to say about IRWD?
Zacks
a month ago
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
GuruFocus.com
a month ago
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
Compare IRWD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.